Methods of treating virally associated cancers with histone deacetylase inhibitors
Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
1. A method of treating an Epstein-Barr virus associated lymphoproliferative disorder in an individual, the method comprising administering to the individual: (a) nanatinostat at a total daily dose from 10 milligrams to 20 milligrams per day; and (b) an effective amount of an antiviral agent selected from the list consisting of aciclovir, ganciclovir, valaciclovir, valganciclovir, and famciclovir, wherein the individual is treated according to a treatment schedule having a duration of one week, and wherein the individual is administered nanatinostat for 4 days of the treatment schedule, thereby treating the Epstein-Barr virus associated lymphoproliferative disorder.
2. The method of claim 1 , wherein the nanatinostat is administered at a total daily dose of 10 milligrams.
3. The method of claim 1 , wherein the nanatinostat is administered at a total daily dose of 20 milligrams.
4. The method of claim 1 , wherein the nanatinostat is administered once per day.
5. The method of claim 1 , wherein the nanatinostat is administered twice per day.
6. The method of claim 1 , wherein the antiviral agent is valganciclovir.
7. The method of claim 6 , wherein the valganciclovir is administered at a total daily dose of 1,800 milligrams.
8. The method of claim 6 , wherein the valganciclovir is administered at a total daily dose of 900 milligrams.
9. The method of claim 6 , wherein the valganciclovir is administered at a total daily dose of 450 milligrams.
10. The method of claim 1 , wherein the antiviral agent is administered every day of the treatment schedule.
11. The method of claim 1 , wherein the antiviral agent is not administered on one or more days of the treatment schedule.
12. The method of claim 1 , wherein the antiviral agent is administered once a day.
13. The method of claim 1 , wherein the antiviral agent is administered twice a day.
14. The method of claim 1 , wherein the antiviral agent is administered orally.
15. The method of claim 1 , wherein the nanatinostat is administered orally.
16. The method of claim 1 , wherein the treatment schedule is repeated.
17. The method of claim 1 , wherein the Epstein-Barr virus associated lymphoproliferative disorder is an Epstein-Barr virus associated leukemia or a lymphoma.
18. The method of claim 17 , wherein the leukemia or lymphoma is a B cell or a T cell leukemia or lymphoma.
19. The method of claim 1 , wherein the individual is afflicted with thrombocytopenia.
20. The method of claim 1 , wherein the individual has a platelet count of less than 150,000 platelets per microliter.
21. A method of treating an Epstein-Barr virus associated lymphoproliferative disorder in an individual, the method comprising administering to the individual (a) nanatinostat at a total daily dose of about 20 mg; and (b) valganciclovir at a total daily dose of about 900 mg according to a weekly treatment schedule, wherein the individual is administered nanatinostat for 4 consecutive days of the treatment schedule, and valganciclovir is administered every day of the treatment schedule.
22. The method of claim 21 , wherein nanatinostat and valganciclovir are administered orally.
23. The method of claim 21 , wherein nanatinostat and valganciclovir are each administered once a day.
24. The method of claim 21 , wherein nanatinostat and valganciclovir are each administered twice a day.
25. The method of claim 21 , wherein the treatment schedule is repeated.